Kura Oncology (KURA) Tops Q4 EPS by 8c

Kura Oncology (NASDAQ: KURA) reported Q4 EPS of ($0.49), $0.08 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Cummins wins battery storage contract for U.S. data center project